Global ETD Search

41	單克隆抗體在中國的發展現狀和未來趨勢 / Current developments and future trends of monoclonal antibody in China 史洪昊 January 2012 (has links) University of Macau / Institute of Chinese Medical Sciences Antibodies, Monoclonal 單克隆抗體 Biotechnology industries -- China 生物科技產業 -- 中國醫藥生物技術業 -- 中國
42	基於部門創新理論的中國生物製藥產業發展分析 / Development of biopharmaceutical in China : an analysis based on sectoral system of innovation 鮑菲飛 January 2011 (has links) University of Macau / Institute of Chinese Medical Sciences 醫藥管理 -- 中華醫藥研究院醫藥生物技術產業 -- 中國 Biotechnology industries -- China 生物科技產業 -- 中國
43	Prospecção tecnológica de óleos essenciais de Schinus terebinthifolius e desenvolvimento de um creme vaginal à base de Ocimum basilicum para tratamento de candidíase Almeida, Mônica Batista de 19 April 2013 (has links) Vaginal candidiasis is a disease with high prevalence in adult women. This study aimed to : ( i ) assess the antiCandida activity of essential oil ( EO ) of S. terebinthifolius front lines of cases of recurrent vaginal candidiasis ; ( II ) produce a antiCandida vaginal cream from OE O. basilicum and evaluate the technological process and this cream antiCandida activity in vitro . The major compounds of OE leaves and dried fruits of S. Terebinthifolius were, respectively, the (+) - camphene (20.1%) and R- ? - pinene (22.1%). In terms of minimum inhibitory concentration (MIC ) and minimum fungicidal , OE Fruit S. terebinthifolius showed bands between 25-200 mg / ml , demonstrating activity against C. parapsilosis ( ATCC 22019 ) and a clinical strain , C. albicans (ATCC 18804) and C. glabrata (ATCC 2001) , not being active on these clinical isolates. Regarding OE leaves, no significant action was observed. The OE dried fruit showed fungistatic , however , no fungicide both OE action, in contrast, leaves and fresh fruits showed antiCandida activity, unless the standard strain of C. glabatra the essential oil from fresh fruits . The major compound of OE O. basilicum (Maria - Bonita) was linalol (72.08%). MIC values ranged between this SO 0.78 to 1.56 mg / ml. Before its antifungal action, was produced a vaginal cream. The samples were stored in these distinct conditions: controlled, refrigerator and oven temperature. In controlled and cooler temperatures, no changes in the formula, however, samples at 45 ° C showed slight changes in texture from the 15th day. It can be concluded that the EO of dried leaves and fruits of S.terebinthifolius Raddi not have antiCandida activity, however, the EO extracted from fresh material Botanical demonstrate such activity . The O. basilicum presents antiCandida action. Tests for antimicrobial activity of vaginal cream in its various concentrations showed satisfactory results compared to a synthetic antifungal.Keywords: Vaginal candidiasis, essential oils, Candida spp., Schinus terebinthifolius Raddi, Ocimum basilicum, vaginal cream, anti-candida. / A candidíase vaginal é uma doença com alta prevalência em mulheres na idade adulta. Este trabalho teve como objetivos: (I) avaliar a atividade antiCandida do óleo essencial (OE) de S. terebinthifolius frente a linhagens de casos de candidíase vaginal recorrente; (II) produzir um creme vaginal antiCandida a partir do OE do O. basilicum e avaliar o processo tecnológico e a atividade antiCandida deste creme in vitro. Os compostos majoritários do OE das folhas e frutos secos de S. terebinthifolius, foram respectivamente, o (+) -Camphene (20,1%) e o R-?-pinene (22,1%). Em se tratando das concentrações inibitórias mínimas (CIM) e fungicidas mínimas, o OE do fruto de S. terebinthifolius apresentou faixas entre 25 - 200 mg/ml, demonstrando atividade contra C. parapsilosis (ATCC 22019) e sua linhagem clínica, C. albicans (ATCC 18804) e C. glabrata (ATCC 2001), não sendo ativo aos isolados clínicos destas. Em relação ao OE das folhas, nenhuma ação significativa foi observada. O OE dos frutos secos apresentou ação fungistática, porém, não houve ação fungicida de ambos os OE, em contrapartida, as folhas e frutos frescos apresentaram atividade antiCandida, salvo, a linhagem padrão de C. glabatra pelo óleo essencial dos frutos frescos. O composto majoritário do OE de O. basilicum (Maria-Bonita) foi o linalol (72,08%). Os valores das CIM deste OE variaram entre 0,78 a 1,56 mg/ml. Diante de sua ação fungicida, foi produzido um creme vaginal. As amostras deste foram armazenadas em condições distintas: temperatura controlada, refrigerador e estufa. Em temperatura controlada e refrigerador, não houve modificações na fórmula, entretanto, as amostras à 45º C, apresentaram modificações leves na textura a partir do 15º dia. Pode-se concluir que os OE de folhas e frutos secos da S.terebinthifolius Raddi não apresentam atividade antiCandida, porém, os OE extraídos do material botânico fresco demonstram tal atividade. O O. basilicum apresenta ação antiCandida. Os testes de atividade antimicrobiana do creme vaginal em suas concentrações distintas demonstraram resultados satisfatórios em comparação a um antifúngico sintético. Palavras-Chave: Candidíase vaginal, óleos essenciais, Candida spp., Schinus terebinthifolius Raddi, Ocimum basilicum, creme vaginal, anti-Candida. Biotecnologia farmacêutica Essencias e óleos essenciais Plantas medicinais Candidíase Candidíase vaginal Candida spp. Schinus terebinthifolius Raddi Ocimum basilicum Creme vaginal Anti-candida Candidiasis Essences and essential oils Medicinal plants Pharmaceutical biotechnology Vaginal candidiasis Essential oils Candida spp. Schinus terebinthifolius Raddi Ocimum basilicum Vaginal cream Anti-candida CNPQ::OUTROS
44	Enabling intellectual property and innovation systems for South Africa's development and competitiveness Sibanda, McLean 16 April 2018 (has links) During the last two decades, there have been a number of policy and legislative changes in respect of South Africa’s intellectual property (IP) and the national system of innovation (NSI). In 2012, a Ministerial Review of the Science, Technology and Innovation (STI) landscape in South Africa made recommendations to improve the STI landscape and effectively the national system of innovation. The study provides a critical review of drafts of the national IP policy published in 2013 as well as the IP Framework released in 2016 for public comment. The review of the IP and the NSI are within the context of the National Development Plan (NDP), which outlines South Africa’s desired developmental goals. South Africa is part of the BRICS group of countries (Brazil, Russia, India, China and South Africa). The South African economy is characterised by a desire to move away from being dependent on resources and commodities, to becoming a more knowledge based and innovation driven economy. It is hoped that such a move would assist the country to address some of the social and economic development challenges facing South Africa, as captured in the NDP. South Africa has a functioning IP system, but its relationship with South Africa’s development trajectory is not established. More particularly, the extent to which the IP system relates to the innovation system and how these two systems must be aligned to enable South Africa to transition successfully from a country based on the production of primary resources and associated commodity-based industries to a viable knowledge-based economy is unclear. The Trade-related Aspects of Intellectual Property Rights (TRIPS Agreement) of the World Trade Organisation (WTO) provides that IP must contribute to innovation and to transfer of technology and knowledge in a manner that is conducive to social and economic welfare. Certain provisions set out the foundations of intellectual property systems within the context of each member state. This study has thus explored the complex, complementary and sometimes contested relationships between IP and innovation, with particular emphasis on the potential of an intellectual property system to stimulate innovation and foster social and economic development. The study has also analysed the interconnectivity of IP and innovation with other WTO legal instruments, taking into account South Africa’s positioning within the globalised economy and in particular the BRICS group of countries. The research involved a critical review of South Africa’s IP and innovation policies, as well as relevant legislation, instruments, infrastructure, IP and innovation landscape, and relationship with international WTO legal instruments, in addition to its performance, given the developmental priorities and the globalised economy. The research documents patenting trends by South Africans using European Patent Office (EPO), Patent Cooperation Treaty (PCT), United States Patents and Trademarks Office (USPTO) databases over the period 1996-2015. A comparative analysis of patenting trends amongst BRICS group of countries has also been documented. The study also documents new findings, observations and insights regarding South Africa’s IP and innovation systems. Some of these, particularly in relation to higher education and research institutions, are directly attributable to the Intellectual Property Rights from Publicly Financed Research and Development Act. More particularly, the public institutions are becoming relevant players in the NSI and are responsible for growth of certain technology clusters, in particular, biotechnology. At the same time, the study makes findings of a decline of private sector participation in patenting as well as R&D investment over the 20-year period. Recommendations are included regarding specific interventions to ensure coherence between the IP and innovation systems. Such coherence and alignment should strengthen the systems’ ability to stimulate innovation and foster inclusive development and competitiveness, which are relevant for addressing South Africa’s socio-economic development priorities. / Mercantile Law / LL. D. Intellectual property IP Patents Commercialisation Start-ups Licensing Innovation Biotechnology Biopharmaceutical Sectors Ecosystem Inclusive growth Economic development TRIPS Agreement Flexibilities BRICS South Africa PCT USPTO EPO Institutions Research and Development (R&D) 346.48068 Intellectual property -- South Africa BRIC countries Economic development -- South Africa
45	Stabil och antibiotikafri läkemedelsproduktion i rekombinant Escherichia coli Benevides, Kristina, Broström, Oscar, Elison Kalman, Grim, Swenson, Hugo, Vlassov, Andrei, Ågren, Josefin January 2017 (has links) Den här rapporten presenterar ett antibiotikafritt, stabilt och kromosombaserat expressionssystem för läkemedelsproduktion i Escherichia coli på beställning av företaget Affibody AB. E. coli-stammen BL21(DE3) valdes som värdorganism för expressionssystemet. Systemet består av en genkassett som innehåller en T7-promotor, en 5′-UTR från genen ompA och en terminatorsekvens från RNA-operonet rrnB. Fyra kopior av genkassetten ska integreras i pseudogenerna caiB, yjjM, hsdS och yjiV. En datormodell som modellerar det egentliga kopietalet i cellerna har skapats i mjukvaran MATLAB, vilket visar att det uppskattas vara maximalt 32 kopior av genkassetten per cell på grund av replikation av kromosomen. Ett högt pH i fermentorn; att använda fed-batch och blandade kolhydratkällor; och att använda stammen BL21(DE3) minskar acetatproduktionen i cellen. En lägre acetatproduktion kan leda till en högre produkthalt. En proteinutbytesmodell för mjukvaran MATLAB har konstruerats för att uppskatta koncentrationen av Affibody®-molekylen i en E. coli cell. copynumber copy-number copy number origin of replication rekombinant proteinexpression läkemedel E. coli antibiotikafri antibiotika expressionssystem expression system escherichia coli kromosom kromosombaserad kromosomal plasmidfri plasmid T7-promotor T7 promotor ompA rrnB autoinduktion auto induktion matlab kopietalmodell utbytemodell stabil pH pseudogen pseudo gen caiB yjjM hsdS yjiV fermentor batch fed-batch kontinuerlig fed batch fermentation Affibody affibody-molekyl affibody-molekyler affibodymolekyl affibodymolekyler bioreaktor acetat acetatbildning acetatproduktion acetatreduktion acetatreducering peptidläkemedel peptider peptid T7-system operator lac-operator operon 5'-UTR 3'-UTR sekundärstruktur mRNA T1 T2 terminator termineringssekvens optimering lac-operon repressor inducering BL21(DE3) BL21 B-stam B stam modell kopietal kopie tal OriC Pharmaceutical Biotechnology Läkemedelsbioteknik

Page generated in 0.0769 seconds